[Effect of mydriasis and accommodation on intraocular pressure and pigment release in patients with the pigment dispersion syndrome]. / Wplyw akomodacji i mydriazy na cisnienie wewnatrzgalkowe i uwalnianie barwnika u chorych z zespolem rozproszonego barwnika.

PURPOSE: To determine if mydriasis and accommodation affect intraocular pressure (IOP) and pigment release in patients with the pigment dispersion syndrome (PDS). MATERIAL AND METHODS: Seventeen patients (34 eyes) diagnosed with PDS were included in the study (10 men and 7 women). Tonometry was performed on all patients before, and at 1 and 2 hours after mydriasis and before, and at 1 and 2 hours after sustained reading. The statistical analysis was performed using the paired T-test. RESULTS: In both tests the differences in intraocular pressure values were not statistically significant. Pigment liberation occurred in 11.8% of patients after mydriasis but was not associated with an increase in IOP. CONCLUSION: Accommodation during sustained reading did not cause significant pigment release or an IOP rise.

Synthetic peptides mimicking antigenic epitope of Helicobacter pylori urease.

Short peptides resembling the Helicobacter pylori urease antigen (UreB F8 Ser-Ile-Lys-Glu-Asp-Val-Gln-Phe) with deleted aspartic acid and glutamic acid residues, anchored through a triazine linker via the N-terminal moiety to cellulose plate were prepared. The peptides were used for binding of antibodies from sera of patients with medically confirmed atherosclerosis. Recognition of the peptides was also tested with anti-Jack beans urease antibodies. The important role of a Gly-Gly spacer separating the peptides from the cellulose support was shown. Different patterns of binding of antibodies from H. pylori infected patients and anti-Jack bean urease antibodies were observed only in the case of pentapeptides. The peptide Gly-Gly-Leu-Val-Phe-Lys-Thr was recognized by most of the tested sera.

Non-epilepsy uses of antiepilepsy drugs.

Antiepileptic drugs (AEDs) affect various neurotransmitters (i.e. GABA, glutamate), receptors (i.e. GABAergic, glutamatergic), and ion channels (i.e. for sodium or calcium) which is responsible for their anticonvulsant activity. However, this broad spectrum of action may be also utilized in other pathological conditions. For example, both conventional and newer AEDs may be used in patients suffering from neuropathic pain, migraine, essential tremor, spasticity, restless legs syndrome and a number of psychiatric disorders (f.e. bipolar disease or schizophrenia). Also, isolated data point to their potential use in Parkinson's or Alzheimer's disease. There is experimental background indicating a potent neuroprotective efficacy of AEDs in numerous models of brain ischemia. However, the clinical data are very limited and this problem requires careful assessment.